180 related articles for article (PubMed ID: 32507101)
1. Advanced papillary thyroid carcinoma responding to nivolumab.
Michel Ocampo M; Lerner J; Tosonian S; Dasanu CA
J Oncol Pharm Pract; 2021 Mar; 27(2):453-456. PubMed ID: 32507101
[TBL] [Abstract][Full Text] [Related]
2. Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.
Choi B; McBride A; Scott AJ
Am J Health Syst Pharm; 2019 Oct; 76(21):1749-1752. PubMed ID: 31612928
[TBL] [Abstract][Full Text] [Related]
3. Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma.
Wehrenberg-Klee E; Goyal L; Dugan M; Zhu AX; Ganguli S
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1799-1802. PubMed ID: 29845347
[TBL] [Abstract][Full Text] [Related]
4. The effect of radiation therapy on the objective response and outcomes with nivolumab for hepatocellular carcinoma.
Smith WH; Law AS; Hulkower M; McGee HM; Lehrer EJ; Schwartz M; Taouli B; Sung M; Buckstein M
Acta Oncol; 2020 Aug; 59(8):940-943. PubMed ID: 32441551
[No Abstract] [Full Text] [Related]
5. Nivolumab for the treatment of hepatocellular carcinoma.
Chiew Woon L; Joycelyn Jie Xin L; Su Pin C
Expert Opin Biol Ther; 2020 Jul; 20(7):687-693. PubMed ID: 32249635
[TBL] [Abstract][Full Text] [Related]
6. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
7. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
Mehnert JM; Varga A; Brose MS; Aggarwal RR; Lin CC; Prawira A; de Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B
BMC Cancer; 2019 Mar; 19(1):196. PubMed ID: 30832606
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
[TBL] [Abstract][Full Text] [Related]
9. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
[TBL] [Abstract][Full Text] [Related]
10. PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review.
Voutsadakis IA
Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):505-510. PubMed ID: 31551142
[TBL] [Abstract][Full Text] [Related]
11. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma.
Friend BD; Venick RS; McDiarmid SV; Zhou X; Naini B; Wang H; Farmer DG; Busuttil RW; Federman N
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643391
[TBL] [Abstract][Full Text] [Related]
12. Severe terminal ileitis induced by single-agent nivolumab administered every four weeks.
Dasanu CA; Plaxe SC; Gupta V; Popescu IM; Grover M; Alvarez-Argote J
J Oncol Pharm Pract; 2020 Sep; 26(6):1516-1519. PubMed ID: 32028838
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab for the treatment of hepatocellular carcinoma.
Finkelmeier F; Waidmann O; Trojan J
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1169-1175. PubMed ID: 30304963
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of Programmed Death 1 Inhibited Progression of Papillary Thyroid Carcinoma in Mice.
Wang H; Chu Q; Ma S; Tao Y
Protein Pept Lett; 2023; 30(5):396-400. PubMed ID: 36876839
[TBL] [Abstract][Full Text] [Related]
15. Evidence for Efficacy of Treatment With the Anti-PD-1 Mab Nivolumab in Radiation and Multichemorefractory Advanced Penile Squamous Cell Carcinoma.
Trafalis DT; Alifieris CE; Kalantzis A; Verigos KE; Vergadis C; Sauvage S
J Immunother; 2018; 41(6):300-305. PubMed ID: 29642086
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab and its use in the second-line treatment of metastatic urothelial cancer.
Raggi D; Necchi A; Giannatempo P
Future Oncol; 2018 Nov; 14(26):2683-2690. PubMed ID: 29927336
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
Samimi M
Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
[TBL] [Abstract][Full Text] [Related]
18. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
19. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous implantation of papillary thyroid carcinoma secondary to percutaneous ethanol injection into nodal metastasis.
Rodríguez-Lomba E; Molina-López I; Parra-Blanco V; Suárez-Fernández R; Ciudad-Blanco C
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e11-e13. PubMed ID: 28653452
[No Abstract] [Full Text] [Related]
[Next] [New Search]
